Patents by Inventor Davide Berlanda

Davide Berlanda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230227873
    Abstract: The invention relates to a process for the preparation of colchicine 1 from colchicoside 2 which comprises enzymatic conversion of colchicoside 2 to 3-O-demethylcolchicine 3, wherein the enzyme used is a cellulase. According to another aspect of the invention, 3-O-demethylcolchicine 3 can be converted to colchicine 1 using an alkylating agent. The invention also relates to a process or enriching the colchicine 1 content of extracts from plants belonging to the Colchicaceae family containing colchicine 1, colchicoside 2 and 3-(9-demethyl colchicine 3, which comprises conversion by means of a colchicoside 2 cellulase to 3-O-demethylcolchicine 3, followed by conversion of 3-O-demethylcolchicine 3 to colchicine 1 using an alkylating agent.
    Type: Application
    Filed: June 14, 2021
    Publication date: July 20, 2023
    Applicant: Indena S.P.A.
    Inventors: Fabio Donzelli, Pietro Allegrini, Alessandro Andreani, Andrea Gambini, Davide Berlanda
  • Publication number: 20220186326
    Abstract: Disclosed is a method for the identification of Vaccinium myrtillus in a botanical composition and a kit specifically designed for its implementation. The method is based on the detection, using PCR amplification, of nucleic acid fragments within a genomic region of Vaccinium myrtillus.
    Type: Application
    Filed: April 6, 2020
    Publication date: June 16, 2022
    Inventors: Valeria LONGO, Davide BERLANDA
  • Patent number: 11241470
    Abstract: Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an ?-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: February 8, 2022
    Assignee: INDENA S.P.A.
    Inventors: Davide Berlanda, Marco Bertani, Ezio Bombardelli, Andrea Gardi, Cesare Ponzone, Fabio Donzelli
  • Publication number: 20170333508
    Abstract: Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an ?-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.
    Type: Application
    Filed: July 7, 2017
    Publication date: November 23, 2017
    Inventors: DAVIDE BERLANDA, MARCO BERTANI, EZIO BOMBARDELLI, ANDREA GARDI, CESARE PONZONE, FABIO DONZELLI
  • Patent number: 8569455
    Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: October 29, 2013
    Assignee: Indena S.p.A.
    Inventors: Paolo Morazzoni, Antonella Riva, Cesare Ponzone, Davide Berlanda, Marcello Duranti, Alessandro Consonni
  • Publication number: 20120172316
    Abstract: A truncated form of ?? chain (e??), the soybean 7S globulin, active in controlling the cholesterol and triglyceride homeostasis in in vitro and in vivo models, was cloned and expressed in the yeast Pichia pastoris. The recombinant polypeptide spanned 142 amino acid residues from the N-terminal side and included the N-terminal extension region of the soybean alpha? subunit. The e?? polypeptide was purified by conventional biochemical techniques and its potential to modulate the activity of the LDL-receptor was evaluated in a human hepatoma cell line (Hep G2) by monitoring the uptake and degradation of labeled LDL.
    Type: Application
    Filed: June 16, 2010
    Publication date: July 5, 2012
    Applicant: INDENA S.P.A.
    Inventors: Paolo Morazzoni, Antonella Riva, Cesare Ponzone, Davide Berlanda, Marcello Duranti, Alessandro Consonni
  • Publication number: 20090169657
    Abstract: Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an ?-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.
    Type: Application
    Filed: December 13, 2006
    Publication date: July 2, 2009
    Inventors: Davide Berlanda, Marco Bertani, Ezio Bombardelli, Fabio Donzelli, Andrea Gardi, Cesare Ponzone
  • Publication number: 20090093397
    Abstract: Extracts obtainable by extraction from Phaseolus sp. with aqueous solutions, characterised by an ?-amylase inhibitor content with an activity equal to or greater than 1,800 USP/mg (HPLC titre equal to or greater than 15% w/w) and a phytohaemagglutinin content of between 1,500 and 6,000 HAU/g, and a process for its preparation.
    Type: Application
    Filed: December 13, 2006
    Publication date: April 9, 2009
    Inventors: Davide Berlanda, Marco Bertani, Ezio Bombardelli, Fabio Donzelli, Andrea Gardi, Cesare Ponzone